市場調査レポート
商品コード
1291344
異常ヘモグロビン症市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
異常ヘモグロビン症市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測 |
出版日: 2023年05月29日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
|
世界の異常ヘモグロビン症の市場規模は、2022年に92億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に9.39%の成長率(CAGR)を示し、2028年までに163億米ドルに達すると予測しています。
異常ヘモグロビン症は、ヘモグロビン分子の構造異常や産生異常を引き起こす遺伝性血液疾患です。鎌状赤血球、サラセミア、ヘモグロビンC、βサラセミアは、一般的なヘモグロビン症の一種です。異常ヘモグロビン症は、遺伝子検査、高速液体クロマトグラフィーによるヘモグロビン検査、日常的な赤血球数測定、ヘモグロビン等電点(Hb IEF)、ヘモグロビン電気泳動(Hb ELP)検査によって発見されます。皮膚の青白さ、息切れ、手足の冷え、疲労感、痛み、手足の腫れなどは、異常ヘモグロビン症の代表的な症状の一部です。広く使われている異常ヘモグロビン症の治療法には、抗生物質、ACE阻害剤、幹細胞移植、輸血、ヒドロキシウレア、鎮痛剤などがあります。
鎌状赤血球症(SCD)やサラセミアなど、さまざまな病態の有病率の増加は、市場の成長を促す重要な要因の1つとなっています。異常ヘモグロビン症は、異常なヘモグロビンが赤血球を変形・損傷させ、硬く粘着性のある状態にすることで発症します。これに伴い、特に、他の様々な慢性疾患にもかかりやすい老年人口の間で貧血の有病率が上昇していることが、市場成長に好影響を与えています。遺伝子の編集、削除、追加、変更、DNAの改変によってヘモグロビン症を治療するCRISPR-Cas9技術の開発など、さまざまな技術的進歩が市場成長に弾みをつけています。これに伴い、ヘモグロビン症の治療に遺伝子治療が広く採用されていることが、市場成長に好影響を与えています。その他の要因としては、ヘルスケア産業の大幅な拡大、手頃な価格で異常ヘモグロビン症を治療するための新規治療法を導入するための研究開発(R&D)活動を促進する様々な政府イニシアティブの実施などがあり、市場に明るい展望をもたらすと予想されています。
The global hemoglobinopathies market size reached US$ 9.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.39% during 2023-2028.
Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.
The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.
Thalassemia
Alpha Thalassemia
Beta Thalassemia
Sickle Cell Disease
Others
The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.
Thalassemia
Alpha Thalassemia
Beta Thalassemia
Sickle Cell Disease
Others
Blood Transfusion
Stem-cell Transplantation
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
Red Blood Cell (RBC) Count
Genetic Testing
High Performance Liquid Chromatography (HPLC)
Hemoglobin Isoelectric Focusing (Hb IEF)
Hemoglobin Electrophoresis (Hb ELP)
Hemoglobin Solubility Test
Hospitals and Clinics
Diagnostics Laboratories
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.
Key Questions Answered in This Report
1. What was the size of the global hemoglobinopathies market in 2022?
2. What is the expected growth rate of the global hemoglobinopathies market during 2023-2028?
3. What has been the impact of COVID-19 on the global hemoglobinopathies market?
4. What are the key factors driving the global hemoglobinopathies market?
5. What is the breakup of the global hemoglobinopathies market based on the type?
6. What is the breakup of the global hemoglobinopathies market based on the treatment?
7. What are the key regions in the global hemoglobinopathies market?
8. Who are the key players/companies in the global hemoglobinopathies market?